MCR Therapeutics will develop peptides to stimulate the production of melanin, a pigment which shields humans against ultraviolet rays and skin cancer.

Pact Pharma has raised a total of $126m, $95m of which just came in a GV-backed round that will fund the entry of its cancer treatments into the clinic.

Scholar Rock, a spinal muscular atrophy therapy developer backed by Kraft Group, floated in the middle of its range.

Jim Berbee first joined Warf's board in 2012 after completing a medical residency at University of Wisconsin-Madison Hospital and Clinics.

ChromaCure has spun out of Université libre de Bruxelles with $19.6m in funding to commercialise treatments for cancer based on a new understanding on tumour metastasis.

The newly-launched UCLA spinout is targeting rare and treatment-resistant forms of epilepsy with an approach drawing on certain kinds of gut bacteria.

The Nan Fung-backed neurological disorder treatment developer has raised $135m in funding in the past two years.

The fund will back dozens of project teams each year, while giving some students and graduates a spot on its investment committee.

Life sciences incubator and company builder Pivotal Bioventure Partners China, part of Nan Fung Group, has closed its latest fund at $150m.